Anti-Influenza Drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 Patients
TOKYO — September 23, 2020 FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereina...
Potential COVID-19 Drug Could Increase Heart Risk: Study
MONDAY, Sept. 21, 2020 — The widely prescrib...
Study highlights failure to recognise risks of epilepsy drug in pregnancy
Doctors are often failing to inform patients about...
Signalling research waves red flag for commercial drug target candidate
Researchers at the Babraham Institute have used th...
New drug shown to improve bone growth in children with achondroplasia in global phase III trial
A phase three global clinical trial led by the Mur...
Ads for pre-exposure prophylaxis drug lawsuits hinder uptake and adherence, study suggests
Over the past year, there has been an influx of ad...
New drug targets clots: A potential treatment for heart attack and stroke prevention
Monash researchers have developed a drug that can ...
Combination drug treatments for COVID-19 show promise in cell culture tests
In the absence of a vaccine for COVID-19, research...
Nation must prepare for COVID-19 related drug shortages
A new paper published online in the Annals of the ...
More efficient drug development with the help of computer models
The coronavirus has the world in its grip. Finding...